HomeCompareBKEAF vs ABBV

BKEAF vs ABBV: Dividend Comparison 2026

BKEAF yields 4.69% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BKEAF wins by $4288.77M in total portfolio value
10 years
BKEAF
BKEAF
● Live price
4.69%
Share price
$1.67
Annual div
$0.08
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4288.87M
Annual income
$4,120,054,081.93
Full BKEAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BKEAF vs ABBV

📍 BKEAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBKEAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BKEAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BKEAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BKEAF
Annual income on $10K today (after 15% tax)
$398.52/yr
After 10yr DRIP, annual income (after tax)
$3,502,045,969.64/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BKEAF beats the other by $3,502,024,913.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BKEAF + ABBV for your $10,000?

BKEAF: 50%ABBV: 50%
100% ABBV50/50100% BKEAF
Portfolio after 10yr
$2144.49M
Annual income
$2,060,039,426.84/yr
Blended yield
96.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BKEAF
No analyst data
Altman Z
0.2
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BKEAF buys
0
ABBV buys
0
No recent congressional trades found for BKEAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBKEAFABBV
Forward yield4.69%3.06%
Annual dividend / share$0.08$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$4288.87M$102.3K
Annual income after 10y$4,120,054,081.93$24,771.77
Total dividends collected$4276.97M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BKEAF vs ABBV ($10,000, DRIP)

YearBKEAF PortfolioBKEAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,638$937.69$11,550$430.00+$88.00BKEAF
2$14,492$2,039.74$13,472$627.96+$1.0KBKEAF
3$20,254$4,747.70$15,906$926.08+$4.3KBKEAF
4$34,075$12,402.66$19,071$1,382.55+$15.0KBKEAF
5$75,461$39,001.14$23,302$2,095.81+$52.2KBKEAF
6$242,185$161,441.27$29,150$3,237.93+$213.0KBKEAF
7$1,227,604$968,466.31$37,536$5,121.41+$1.19MBKEAF
8$10,489,305$9,175,769.32$50,079$8,338.38+$10.44MBKEAF
9$157,770,651$146,547,094.08$69,753$14,065.80+$157.70MBKEAF
10$4,288,868,678$4,120,054,081.93$102,337$24,771.77+$4288.77MBKEAF

BKEAF vs ABBV: Complete Analysis 2026

BKEAFStock

The Bank of East Asia, Limited, together with its subsidiaries, provides various banking and related financial services. Its personal banking services include corporate, individual, savings, current, time deposit, and supreme accounts; and fixed and call deposits, foreign currency deposits, MAS services, and auto-payroll products, as well as safe deposit boxes and remittance services. The company also provides corporate banking services, such as SME loans and financing guarantee schemes; corporate and commercial financing products, including syndicated and construction loans, acquisition and structured financing, working capital financing, share financing and IPO-related loans, and commercial mortgages; trade finance services and expert trade solutions; factoring services; import and export trade finance; guarantee services; eTradeConnect that allows buyers and sellers to connect, transact, share information, and submit applications for financing through a single platform; cash management services; corporate wealth management products; foreign exchange and treasury products; trade settlement and financing services; onshore and offshore loans; and marine cargo, property, trade credit, employee compensation, pet, medical, life, savings, and endowment insurance plans. In addition, it offers private banking services comprising investment advisory services; investment solutions, such as unit trusts, linked deposits, currency trading and management, global equities and bonds investments, structured products, and options and derivatives; portfolio management services; securities and futures broking services; cyber banking, credit cards, and ATM; and various international services. The company operates 150 outlets in Hong Kong, rest of Greater China, Southeast Asia, the United Kingdom, and the United States. The Bank of East Asia, Limited was incorporated in 1918 and is headquartered in Central, Hong Kong.

Full BKEAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BKEAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BKEAF vs SCHDBKEAF vs JEPIBKEAF vs OBKEAF vs KOBKEAF vs MAINBKEAF vs JNJBKEAF vs MRKBKEAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.